B A C K G R O U N D
Based on compelling evidence from epidemiological analysis of numerous large cohorts, and supported by convincing experimental studies that revealed phosphate toxicity, targeting hyperphospataemia in chronic kidney disease (CKD) is widely accepted and integrated into guidelines [1] . The treatment options are dietary intervention, modifying dialysis schemes for those with end-stage renal disease, targeting severe hyperparathyroidism and pharmacotherapy such as phosphate binders. For none of these interventions, despite their potential negative impact on quality of life, side effects and costs, does definite proof of benefit exist. In light of the unresolved battle that is lasting for decades among clinicians, researchers, guideline and policymakers, and pharmaceutical companies on the question of what the best phosphate binder is, it is remarkable that selecting a specific drug for hyperphosphataemia is among the most frequently made therapeutic decisions in the clinical care for patients with advanced CKD.
When considering initiating phosphate-lowering treatment, the goals of treatment should be taken into account. Although the incentive to initiate, and the parameter to titrate these drugs is the serum phosphate concentration, the goal should be a substantial reduction of absolute risk for a clinical event. In the setting of a high non-modifiable background risk, as frequently exists in older patients on dialysis with severe comorbid conditions, this assumed risk reduction may be limited or absent, which renders even small increases in the burden of treatment unacceptable.
With these considerations in mind the next step would be to identify a specific compound to prescribe. Several aspects could contribute to this decision.
E F F I C A C Y I N T E R M S O F S E R U M P H O S P H A T E C O N C E N T R A T I O N C O N T R O L
All marketed phosphate binders lower serum phosphate concentrations [2] . Therefore, in general, this aspect is not helpful in selecting an initial phosphate binder. However, patient-specific factors appear to influence efficacy and may be explained by differences in gastric pH, competition with other compounds for binding in different segments of the gastrointestinal tract, or differences in disintegration of the pill itself. As these factors are largely unpredictable, this may emerge during follow-up. Attained phosphate control in clinical trials examining a range of binders, a very different scenario from real-world clinical practice, was best for iron-based binders in a network meta-analysis [3] .
P I L L B U R D E N
Although efficacy exists for all phosphate binders, differences in pill burden to achieve this can be large, ranging from three to four per day for lanthanumcarbonate and sucroferric oxyhydroxide to over nine per day for sevelamer carbonate and calcium-containing binders [4] . Pill burden may negatively affect adherence to prescription, and thereby negatively impact on effectiveness.
S I D E E F F E C T S
All phosphate binders can have side effects, and most of these are gastrointestinal in nature, mainly consisting of nausea, diarrhoea or constipation. These side effects in general are selflimiting, usually after cessation of the offending compound. It is also important to stress that in the majority of patients these side effects do not occur (or are not recognized to be caused by the phosphate-binding agent). Unfortunately, it is impossible to predict who will and who will not experience a side effect. Therefore, the potential for side effects generally does not influence treatment decision on initial therapy, which is a matter of trial and error, together with clinical awareness and monitoring.
A more insidious side effect may be accumulation. This may be of relevance in particular for long-term use of aluminumcontaining binders, contributing to bone disease, and for calcium-containing binders, promoting more rapid progression of arterial wall calcification [5, 6] .
E F F I C A C Y I N T E R M S O F R I S K R E D U C T I O N F O R C L I N I C A L E V E N T S
As outlined above, the primary aim of any phosphate-lowering intervention is to improve the risk profile for clinically relevant events, and based on the assumed mechanism of phosphate toxicity, in particular cardiovascular events or (all-cause) mortality. The debate on the usefulness of any phosphate binder or a 2018 specific one is dominated by this aspect. Most studies focused on all-cause mortality as primary outcome, but no study compared a binder versus placebo in the setting of overt hyperphosphataemia. Direct head-to-head studies are scarce and essentially confined to the comparison between sevelamer and calcium-based binders. Systematic reviews and a meta-analysis of these studies concluded that sevelamer is a better option than calcium-containing binder, but also recognized that individual studies on which that conclusion is based have a varying degree of bias, one of which was the high average dose of elemental calcium used in the comparator arm [7] . In the absence of other direct head-to-head studies comparing different treatment options, a network meta-analysis can shed some light on the dilemma of how to weigh this aspect in drug selection. This analysis confirmed the superiority of sevelamer over calciumcontaining binders (with the same caveats as indicated above) in terms of all-cause mortality reduction, and found no differences among the novel non-calcium-containing binders, which included sevelamer [3] . There were insufficient data to make such an analysis or to investigate other clinically relevant endpoints.
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I N T E R A C T I O N S
Most phosphate binders can interact with levothyroxine especially if ingested within the same time window. Both calciumcontaining binders and sevelamer can limit gastrointestinal uptake of several antimicrobial drugs. Calcium-containing binders can inhibit uptake of oral iron, while sevelamer can lower trough levels of some immune suppressants. Most binders, with the exception of sevelamer and sucroferric oxyhydroxide, can bind vitamin K [8] .
C O M B I N A T I O N T H E R A P Y
Using two different phosphate binders in parallel has the rationale that at different segments in the gastrointestinal tract different binders may have different binding capacity. In the Current Management of Secondary Hyperparathyroidism: A Multicenter Observational Study (COSMOS) use of combination therapy was associated with lower serum phosphate concentrations [9] . A possible drawback of combination therapy is that it may increase the likelihood of side effects and drug interaction.
C O S T S
In general, novel non-calcium-based phosphate binders are much more expensive than calcium-based and aluminumbased binders. In most countries, the price differences among these new binders (iron-based, lanthanum and sevelamer) are negligible on a daily basis. Generic formulations are available for sevelamer and will soon be available for lanthanum as well. These will be cheaper than the branded compounds.
P A T I E N T P R E F E R E N C E S
The lack of proof of benefit of one binder over the other (with the exception of higher doses of calcium-containing binders), and the likelihood of comparable safety and efficacy of some, should lead to high priority being given to patients' preferences. Importantly these preferences cannot be inferred from, for instance, pill number or even side effects, because patients' tolerance and acceptance of treatment may depend on completely different subjective aspects. These should be evaluated by just asking. Taking account of this subjective aspect was shown to improve adherence and phosphate control [10] .
C O N C L U S I O N S
Several aspects should be taken into account when selecting initial phosphate-binder therapy, titrating its dose and deciding to switch strategy. These aspects can have different weights in different circumstances, like availability, reimbursement and patient characteristics. Taking these factors into account may assist in selecting the right strategy for an individual patient, by shared decision-making. A potential algorithm to do so is shown in Figure 1 .
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